Avid Radiopharmaceuticals

Avid Radiopharmaceuticals

Avid Radiopharmaceuticals is developing new molecular imaging agents capable of changing the medical management of significant chronic human diseases; allowing early treatment and management of people at risk – before symptoms of disease can develop. Avid’s pipeline of imaging compounds has the potential to dramatically alter the clinical course of Alzheimer’s disease, Dementia with Lewy Bodies, Parkinson’s disease, and Diabetes Mellitus.

Acquired by Eli Lilly in December 2010

<< Portfolio